Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04920955
Status:
COMPLETED
Last Update Posted:
2024-03-19
First Post:
2021-06-02
Brief Title:
Relapse Markers for Colorectal Cancer
Sponsor:
Novigenix SA
Organization:
Novigenix SA
Study Overview
Official Title:
Evaluation of a Novel Blood Multi-marker Test for the Detection of Colorectal Cancer Relapse
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RELMA-C
Brief Summary:
This is an observational case-control study which enroll metastatic and non-metastatic colorectal cancer CRC patients The objective of this study is to evaluate a novel blood multi-marker test for the detection of relapse in colorectal cancer patients This test is based on whole-blood transcriptomic signatures and circulating tumor methylated DNA markers The patients will be enrolled into 4 study groups two cross-sectional and two longitudinal groups to follow up patients up to 36 months from primary tumor resection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None